McKesson Corporation (MCK) News
Follow McKesson Corporation (MCK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 34 public stories across 22 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
McKesson Reports Fiscal Q2 2027 Revenue of $110.96 Billion, Raises EPS Guidance
Fiscal Q2 revenue rose 8% year over year to $110.96 billion, while adjusted EPS was $11.68 and exceeded analyst estimates. McKesson raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. The company also extended its
EQUITY | Nov 05, 2026, 09:34 PM UTC
M
McKesson Raises Fiscal 2027 Adjusted EPS Outlook to $45.60-$46.40
EARNINGS | Nov 04, 2026, 10:32 PM UTC
M
McKesson Reports Second-Quarter Revenue of $110.96 Billion
McKesson reported second-quarter 2026 revenue of $110.96 billion, up 7.6% year over year. Net income rose 9.7% to $1.22 billion, and diluted EPS increased 17% to $10.44.
EQUITY | Nov 04, 2026, 10:32 PM UTC
M
McKesson Announces Fiscal 2027 Second-Quarter Earnings Release Availability
EQUITY | Nov 04, 2026, 09:54 PM UTC
M
McKesson reports fiscal second-quarter results
McKesson reported its fiscal second-quarter results, according to the Associated Press.
EQUITY | Nov 04, 2026, 09:48 PM UTC
M
McKesson Reports Fiscal 2027 Results, Raises Full-Year Adjusted EPS Guidance
McKesson released fiscal 2027 second-quarter results and raised its full-year adjusted EPS guidance.
EARNINGS | Nov 04, 2026, 09:36 PM UTC
M
McKesson Q2'26 Earnings Preview
McKesson is scheduled to report Q2'26 results November 4 after the market closes.
EQUITY | Nov 03, 2026, 12:01 PM UTC
L
Sanofi settles U.S. antitrust lawsuit over Lantus
Sanofi settled a U.S. antitrust lawsuit concerning competition for its diabetes drug Lantus.
REGULATION | Oct 28, 2026, 08:42 PM UTC
M
McKesson Q2'26 Earnings Preview
McKesson is scheduled to report Q2'26 results after the market closes on November 4.
EQUITY | Oct 28, 2026, 11:00 AM UTC
H
Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen Bankruptcy
New On The Block Caribou Biosciences, Inc. (NASDAQ: CRBU ), a clinical-stage CRISPR genome-editing biopharmaceutical company, is exploring strategic alternatives to maximize stockholder value and plans to discontinue fur
LIVE | Oct 09, 2026, 07:03 PM UTC
M
CD&R, McKesson to Acquire Option Care Health for $5.8B
CD&R and McKesson are acquiring Option Care Health, an at-home infusion therapy provider, for approximately $5.8 billion, including debt. CD&R will hold a majority interest of about 51%.
EQUITY | Oct 06, 2026, 12:41 PM UTC
M
CD&R, McKesson Sign Deal to Acquire Option Care Health
CD&R and McKesson Corporation have entered into an agreement to acquire Option Care Health.
EQUITY | Oct 06, 2026, 12:11 PM UTC
H
Option Care Health Stock Surges on $5B McKesson Buyout Talks
Option Care Health (OPCH) shares surged approximately 22% in after-hours trading following a report that McKesson (MCK) and private equity firm Clayton Dubilier & Rice are nearing a deal for a buyout valued at over $5 bi
MNA | Oct 05, 2026, 10:28 PM UTC
M
McKesson Reaches Agreement in Principle to Extend CVS Health Partnership
McKesson (MCK) shares rose 4.4% after reaching an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
EQUITY | Oct 01, 2026, 05:09 PM UTC
H
Cardinal Health, McKesson Double Down on CVS Deals Through 2032
Cardinal Health Inc. (NYSE: CAH ) on Thursday entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health Inc. (NYSE: CVS ) through June 30, 2032. Distribution Partnership With C
LIVE | Oct 01, 2026, 03:59 PM UTC
H
McKesson shares are trading higher after the company reiterated its FY27 adjusted EPS guidance.
McKesson shares are trading higher after the company reiterated its FY27 adjusted EPS guidance.
LIVE | Oct 01, 2026, 01:30 PM UTC
H
McKesson Reiterates FY27 Adjusted EPS Outlook Range Of $44.20 To $45
McKesson Corporation (NYSE: MCK ) announced today it is reaffirming its fiscal year 2027 adjusted EPS guidance of $44.20 to $45.00 and its long-term adjusted EPS growth rate of 13% to 16%. Further updates will be provide
LIVE | Oct 01, 2026, 12:05 PM UTC
L
Weekly Recap: Fiscal 2027 Q2 results and Morgan Stanley Vintage pick
McKesson Corporation (NYSE:MCK) will report fiscal 2027 Q2 results after the Nov. 4, 2026 close with a live webcasted call at 4:30 PM ET, and Morgan Stanley has named NYSE:MCK a top-15 Vintage Values 2027 pick, citing hi
EARNINGS | Sep 28, 2026, 11:06 AM UTC
H
MCK - McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
MCK - McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
EARNINGS | Sep 23, 2026, 12:08 PM UTC
H
McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2027 financial results after market close on Wednesday, November 4, 2026. The company will host a live webcast of the earnings conference call for i
EARNINGS | Sep 23, 2026, 12:00 PM UTC
M
McKesson lifts fiscal EPS guidance; Wellverse sales rise, profit falls
McKesson raised fiscal EPS guidance to $44.20–$45.00. Wellverse Medical-Surgical posted ~4% sales growth but ~20% drop in adjusted operating profit, and the company plans an IPO in H2 2027 for Wellverse.
EARNINGS | Sep 21, 2026, 11:28 AM UTC
M
MCK outlook supported by Q1 growth and $2.25B Precision acquisition
MCK said strategic focus on oncology and supply chain, including its $2.25B Precision Medicine Group acquisition, supports a positive outlook alongside robust Q1 growth, AI and technology investments, and biosimilar oppo
MNA | Sep 08, 2026, 01:34 PM UTC
M
MCK Q1 growth and Precision Medicine Group acquisition lift outlook
MCK cited strong Q1 growth across key segments, with AI and automation driving productivity. Strategy highlights oncology/biopharma/supply chain and the $2.25B Precision Medicine Group acquisition.
MNA | Sep 08, 2026, 01:00 PM UTC
L
MCK - ShinyHunters has leaked the data of McKesson Corporation
MCK - ShinyHunters has leaked the data of McKesson Corporation
EQUITY | Sep 03, 2026, 04:30 PM UTC
L
McKesson Reports Cyberattack
McKesson Reports Cyberattack
EQUITY | Aug 28, 2026, 08:44 PM UTC
L
McKesson says it has not determined material incident impact
McKesson has not determined that an incident is material or likely to have material impact on its financial condition or results of operations.
EQUITY | Aug 28, 2026, 08:23 PM UTC
M
McKesson signs agreement to acquire Precision Medicine Group
McKesson (MCK) signs an agreement to acquire Precision Medicine Group, LLC, according to TradeXchange Newsdesk, with no deal terms provided in the feed.
MNA | Aug 25, 2026, 12:02 PM UTC
L
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
Near 200dma support LIN KKR OGE MCK STE APG MLI WRB FHB GMED SRPT UTHR GNRC GNTX CMI RITM WTM RMD WFRD
EQUITY | Aug 20, 2026, 07:27 PM UTC
M
RBC initiates MCK at Sector Perform, $845 target
RBC Capital initiates McKesson (MCK) at Sector Perform with an $845.00 price target.
EQUITY | Aug 19, 2026, 11:55 AM UTC
L
RBC starts McKesson at Sector Perform, $845 target
RBC initiates McKesson (MCK) at Sector Perform with an $845 price target; the alert gives no additional catalyst or rationale.
EQUITY | Aug 19, 2026, 11:28 AM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
M
McKesson Target Raised
Baird raises target price to $1,015
EQUITY | Aug 06, 2026, 03:30 AM UTC
H
MCK - McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
MCK - McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
EARNINGS | Aug 05, 2026, 08:22 PM UTC
H
McKesson Raises FY2027 Adj EPS Guidance from $43.80-$44.60 to $44.20-$45.00 vs $44.26 Est; Sees Sales $423.601B-$439.739B vs $431.419B Est
McKesson (NYSE: MCK ) raises FY2027 Adj EPS guidance from $43.80-$44.60 to $44.20-$45.00 vs $44.26 analyst estimate. sees sales of $423.601 billion-$439.739 billion vs $431.419 billion analyst estimate.
EARNINGS | Aug 05, 2026, 08:12 PM UTC
H
MCK McCormick to seek secondary London listing after Unilever food business merger completes
MCK McCormick to seek secondary London listing after Unilever food business merger completes
MNA | Jul 23, 2026, 10:32 AM UTC
L
MCK McKesson Corporation raises quarterly dividend by 15% to $0.94 per share
MCK McKesson Corporation raises quarterly dividend by 15% to $0.94 per share
EQUITY | Jul 22, 2026, 12:10 PM UTC
L
Near 200dma support AWK NI NEE BDX FAST BLK PG WAL ITT MCK WTRG BRKB ATO DKS
Near 200dma support AWK NI NEE BDX FAST BLK PG WAL ITT MCK WTRG BRKB ATO DKS
EQUITY | Jul 20, 2026, 04:42 PM UTC
L
Near 200dma resistance HON DHR FNF MLI MCK BRKB SEB BJ VLTO RPM EMR PCTY TOST
Near 200dma resistance HON DHR FNF MLI MCK BRKB SEB BJ VLTO RPM EMR PCTY TOST
EQUITY | Jul 16, 2026, 03:26 PM UTC